Santhera Pharmaceuticals Holding AG

Headquarters: Pratteln, Switzerland

Employees: 86

show_chart SIX: SANN +3.35%

Market Cap

CHF96.6 Million

CHF as of July 1, 2023

US$108.0 Million

history Market Cap History

Santhera Pharmaceuticals Holding AG market capitalization over time

Evolution of Santhera Pharmaceuticals Holding AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Santhera Pharmaceuticals Holding AG

Detailed Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. It is developing Duchenne muscular dystrophy (DMD) product portfolio to treat patients irrespective of causative mutations, disease stage, or age. The company's late stage drug candidate include vamorolone, which is being developed as treatments for DMD. Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil and an exploratory gene therapy approach targeting congenital muscular dystrophies. The company also out-licenses ex-North American rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. It has collaboration agreement with Cold Spring Harbor Laboratory to investigate the potential of lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase, as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome. Santhera Pharmaceuticals Holding AG is headquartered in Pratteln, Switzerland.

Stocks & Indices

Santhera Pharmaceuticals Holding AG has the following listings and related stock indices.

Stock: SIX: SANN



Hohenrainstrasse 24

Pratteln, 4133


Phone: 41 61 906 89 50

Fax: 41 61 906 89 51